Biologic agents have been proven to be highly effective in treating inflammatory diseases such as rheumatoid arthritis (RA), adult ulcerative colitis (UC), psoriasis, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and adult and pediatric Crohn’s disease (CD). Unfortunately, many health care plans restrict the use of these agents due to high cost.
Biosimilars are biopharmaceuticals that have been genetically engineered to be highly similar – meaning any difference is minor and not clinically meaningful – to an already existing approved biologic product. While biosimilars have been available in Europe since 2005, the first biosimilar monoclonal antibody in the United States, infliximab, has recently been approved for use in treating an array of inflammatory diseases.
Tune into these NEW CMEO Snacks today, featuring expert faculty, and join Dr. Leonard Calabrese on Wednesday, September 20th at NOON for a LIVE Q&A to further discuss the interchangeability, efficacy, and safety of biosimilars in the treatment of ID!
Get started on these 15-minute activities now
Register today for the LIVE Q&A with Dr. Calabrese
Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases
Date: September 20, 2017
Time: 12:00p – 12:30p ET
Russell D. Cohen, MD, FACG, AGAF
Edward Li, PharmD, MPH, BCOP
Leonard H. Calabrese, DO